ReviewTransactions of the American Clinical and Climatological Association2008
In search of the holy grail of antifungal therapy.
Review in Transactions of the American Clinical and Climatological Association, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 62 citations in OpenAlex.
- The Hidden Fortress: A Comprehensive Review of Fungal Biofilms with Emphasis onJournal of fungi (Basel, Switzerland) · 2025Review
- Molecular Cloning, Heterologous Expression, Purification, and Evaluation of Protein-Ligand Interactions of CYP51 ofBiomedicines · 2023Article
- Production, Detection, Extraction, and Quantification of Polyene Antibiotics.Methods in molecular biology (Clifton, N.J.) · 2021Article
- Tetrahydrocarbazoles are a novel class of potent P-type ATPase inhibitors with antifungal activity.PloS one · 2018Article
- Genetic validation and spectroscopic detailing of DHN-melanin extracted from an environmental fungus.Biochemistry and biophysics reports · 2017Article
- Biomimetically engineered Amphotericin B nano-aggregates circumvent toxicity constraints and treat systemic fungal infection in experimental animals.Scientific reports · 2017Article
- Crystal Structure of the New Investigational Drug Candidate VT-1598 in Complex with Aspergillus fumigatus Sterol 14α-Demethylase Provides Insights into Its Broad-Spectrum Antifungal Activity.Antimicrobial agents and chemotherapy · 2017Article
- Immune-Stimulatory and Therapeutic Activity ofJournal of immunology research · 2017Article
- A complex game of hide and seek: the search for new antifungals.MedChemComm · 2016Article
- Blad-Containing Oligomer Fungicidal Activity on Human Pathogenic Yeasts. From the Outside to the Inside of the Target Cell.Frontiers in microbiology · 2016Article
- The Mechanistic Targets of Antifungal Agents: An Overview.Mini reviews in medicinal chemistry · 2016Review
- Bioactive Secondary Metabolites Produced by the Fungal Endophytes of Conifers.Natural product communications · 2015Review
- Evaluation of intravenous regional perfusion with amphotericin B and dimethylsulfoxide to treat horses for pythiosis of a limb.BMC veterinary research · 2015Article
- Potential Use of Phenolic Acids as Anti-Candida Agents: A Review.Frontiers in microbiology · 2015Review
- Identification of New Antifungal Compounds Targeting Thioredoxin Reductase of Paracoccidioides Genus.PloS one · 2015Article
- Attenuation of Candida albicans virulence with focus on disruption of its vacuole functions.Journal of oral microbiology · 2014Review
- Advances in targeting the vacuolar proton-translocating ATPase (V-ATPase) for anti-fungal therapy.Frontiers in pharmacology · 2014Review
- The diversity of anti-microbial secondary metabolites produced by fungal endophytes: an interdisciplinary perspective.Frontiers in microbiology · 2013Article
- In vitro interactions between aspirin and amphotericin B against planktonic cells and biofilm cells of Candida albicans and C. parapsilosis.Antimicrobial agents and chemotherapy · 2012Article
- Calcium-activated-calcineurin reduces the In vitro and In vivo sensitivity of fluconazole to Candida albicans via Rta2p.PloS one · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ideal antifungal agent remains an elusive goal for treatment of life-threatening systemic fungal infections. Such an agent would have broad antifungal activity, low rates of resistance, flexible routes of administration, few associated adverse events, and limited drug-drug interactions. Only three of the seven classes of antifungal agents currently available are suitable for treatment of systemic infection: the polyenes, the azoles, and the echinocandins. None match all the characteristics of an ideal agent, the Holy Grail of antifungal therapy. Academia and industry need to collaborate in the search for new lead antifungal compounds using traditional screening methods as well as the new pharmacogenomics methods. Enhancing efficacy and reducing toxicity of the currently available therapeutic agents is also another important avenue of study. As an example, the Mycosis Research Center at the University of Mississippi Medical Center has identified pyogenic polyenes in commercial preparations of amphotericin B deoxycholate which correlate with infusion related toxicities. A highly purified formulation of amphotericin B appears promising, with a better therapeutic index compared to its parent compound as evidenced by results of in vitro and in vivo studies reviewed in this presentation.
Indexed as
Identifiers
18596853PMC2394691W42568365What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.